Advertisement

European Journal of Clinical Pharmacology

, Volume 43, Issue 6, pp 657–659 | Cite as

Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency

  • Mitsuyoshi Nakashima
  • J. Yamamoto
  • M. Shihata
  • T. Uematsu
  • H. Shinjo
  • T. Akahori
  • H. Shioya
  • K. Sugiyama
  • Y. Kawahara
Short Communications

Summary

The pharmacokinetics of temocapril hydrochloride, a novel prodrug-type angiotensin-I converting enzyme (ACE) inhibitor, has been studied in patients with mild (Group II) to severe (Group III) renal insufficiency in comparison with subjects with normal renal function (Group I).

The pharmacokinetic parameters of the active diacid metabolite, including Cmax, AUC and half-life (t1/2), showed only slight changes between the three groups: AUC (0–∞) was significantly larger in Group III than Group I, and t1/2 tended to be prolonged in Group III, but the change was not significant.

The urinary recovery of the diacid was significantly decreased in Group III. (Group I, 28.1 %, Group II, 21.6 %, Group III, 12.8 %). Compared with other ACE inhibitors, which are mainly excreted through the kidney, the plasma concentration of the active diacid metabolite was hardly influenced by renal function. It was speculated that lowering of the dose of temocapril might be recommended only in patients with severe renal insufficiency.

Key words

Temocapril, Renal insufficiency angiotensin-I converting enzyme inhibitor, pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jane F, Kuan TS, Mora J, Walter U, Eckert H-G, Hajdu P, Metzger H (1987) Influence of renal function on the pharmacokinetics of ramipril (HOE 498). Am J Cardiol 59: 70D-78DGoogle Scholar
  2. Jackson B, Cubela RB, Conway EL, Johnston CI (1988) Lisinopril pharmacokinetics in chronic renal failure. Br J Clin Pharmacol 25: 719–724Google Scholar
  3. Jenkins AC, Dreslinski GR, Tadros SS, Greol JT, Fand R, Herczeg SA (1985) Captopril in hypertension; Seven years later. J Cardiovase Pharmacol 7 [Suppl I]: S96-S101Google Scholar
  4. Lowenthal DT, Irvin JD, Merrill BA, Saris S, Ulm E, Goldstein S, Hichens M, Klein L, Till A, Harris K (1985) The effect of renal function on enalapril kinetics. Clin Pharmacol Ther 12: 661–666Google Scholar
  5. Oizumi K, Koike H, Sada T, Miyamoto M, Nishino H, Matsushita Y, Iijima Y, Yanagisawa H (1988) Pharmacological profiles of CS622, a novel angiotensin converting enzyme inhibitor. Jpn J Pharmacol 48: 349–356Google Scholar
  6. Onoyama K, Kumagai H, Inenaga T, Nanishi F, Okuda S, Oh Y, Omae T, Hayashi K, Fujishima M (1986) Pharmacokinetic properties of a new angiotensin I-converting enzyme inhibitor in patients with chronic renal failure. Curr Ther Res 39: 671–680Google Scholar
  7. Shioya H, Shimojo M, Kawahara Y (1989) Determination of a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite in plasma and urine by gas chromatography-mass spectrometry using negative ion chemical ionization. J Chromatogr 496: 129–135Google Scholar
  8. Yamaoka K, Nakagawa T, Uno T (1978) Statistical moment in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Mitsuyoshi Nakashima
    • 1
  • J. Yamamoto
    • 2
  • M. Shihata
    • 2
  • T. Uematsu
    • 1
  • H. Shinjo
    • 2
  • T. Akahori
    • 2
  • H. Shioya
    • 3
  • K. Sugiyama
    • 4
  • Y. Kawahara
    • 3
  1. 1.Department of PharmacologyHamamatsu University School of MedicineHamamatsuJapan
  2. 2.Department of Internal MedicineKakegawa City HospitalKakegawaJapan
  3. 3.Product Development Laboratories Sankyo Co. Ltd.TokyoJapan
  4. 4.New Drug Development Department ISankyo Co., Ltd.TokyoJapan

Personalised recommendations